FEMY

FEMASYS INC

Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001339005 Healthcare & Medical Devices

$1.41 −0.09 (−6.00%)

Oct 26 4:00 PM ET · prev $1.50

Market cap

$13.1M

Nano cap

Consensus

Buy

89% Buy or better · 9 analysts

Median target

$10.00

+609% · range $10.00–23.00

Next earnings

Nov 12

in 17 days · EPS est. −$0.60

1 year

−90.1%

from $14.18 · Oct 27

30 days

−40.8%

from $2.38

52-week range

$1.41–20.80

at the low

Avg volume 20D

114.5K

shares / day

Short interest

577.2K

≈6.9% of shares · −5.8%

Days to cover

7.4

at average volume

Insider net

+$134.0K

5 buyers · 0 sellers · 12 mo

Filing reports

analyzed by SecBot

SecBot read BEARISH 7 reports · 90 days

Balance 3 bearish · 1 bullish · 1 mixed · 2 neutral oldest → newest, height = score

Avg score

·High conf. 5/7 ·Next Earnings date, Nov 12, 2026

Strongest NEUTRAL Empery Asset Management, LP filed a Schedule 13G disclosing a 5.6% passive stake in Femasys Inc…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Mar 31 Femasys reported full-year 2025 revenue of $2.29M, up 40.8% YoY, wit…
B Aug 7 5 insiders buy $134.0K at $3.20
E Aug 7 Offering: Femasys Secures $30 Million Private Placement, with Potent…
R Aug 7 Femasys announced a $30 million private placement led by Nantahala C…
R Aug 12 CEO Kathy Lee-Sepsick and CFO Dov Elefant each purchased $50K worth…
R Aug 14 Femasys reported Q2 2026 revenue of $331,827 (down 18.9% YoY) and a…
X Aug 14 Short interest jumps 64.2% to 435.0K
X Aug 31 Short interest jumps 36.3% to 593.1K

Signal stack

Where each data set points today.

InsidersBULLISH

5 insiders bought $134.0K at an average $3.20. No open-market sales. Price is 56% below their cost.
AnalystsBULLISH

8 of 9 rate it Buy or better. Every target is above the price.
EstimatesRISING

Current-quarter EPS estimate −$1.500 → −$0.605 over 90 days. 2 up, 0 down in 30 days.
Short sellersSTEADY

Short interest −5.8% to 577.2K shares. 7.4 days to cover, ≈6.9% of shares.
TrendDOWNTREND

41% below its 50-day average. New closing low $1.41 on Oct 26.

Who's buying

13F

Top holder	Shares	Value
VANGUARD CAPITAL MANAGEMENT LLC	62,232	$260.1K
JANE STREET GROUP, LLC	52,511	$219.5K
GEODE CAPITAL MANAGEMENT, LLC	30,920	$129.3K
UBS Group AG	18,777	$78.5K
CITADEL ADVISORS LLC	16,921	$70.7K
VANGUARD FIDUCIARY TRUST CO	12,492	$52.2K
OSAIC HOLDINGS, INC.	2,397	$10.0K
BlackRock, Inc.	1,784	$7.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts

Buy 89% rate it Buy or better

Strong Buy2Buy6Hold1Sell0Strong Sell0

12-month targets · 3 analysts

$1.41 $10.00 $10.00 $23.00

Price is below the lowest target. Median implies +609%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 18, 2026	Lake Street MAINTAIN	MAINTAIN	Buy
Aug 14, 2026	Maxim Group MAINTAIN	MAINTAIN	Buy

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Upcoming

Nov 12, 2026

Earnings date

FEMY Q3 2026 Earnings Scheduled — 2026-11-12

Recent

Oct 20, 2026

Announcement

Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs

First in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for OB/GYNs and their patients...

Sep 2, 2026

Reg SHO list

Reg SHO Threshold: FEMY exited the threshold list

FEMASYS INC COM NEW (DE) | On list since 2026-08-26

Aug 26, 2026

Reg SHO list

Reg SHO Threshold: FEMY entered the threshold list

FEMASYS INC COM NEW (DE) | 5+ consecutive settlement days of fails-to-deliver ≥10k shares and ≥0.5% of shares outstanding

Aug 14, 2026

Earnings

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ®…

Aug 7, 2026

Offering

Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million

-- Potential proceeds would be received upon full cash exercise of warrants -- ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ…

Insider ledger

Form 4

$134.0K

bought · 5 insiders

sold · 0 insiders

−55.9%

vs their $3.20 cost

Date	Insider	Type	Value
Aug 7, 2026	Lee-Sepsick Kathy Chief Executive Officer	BUY	$50.0K
Aug 7, 2026	Lee-Sepsick Kathy Chief Executive Officer	AWARD	15,625 sh
Aug 7, 2026	Lee-Sepsick Kathy Chief Executive Officer	AWARD	15,625 sh
Aug 7, 2026	Elefant Dov Chief Financial Officer	BUY	$50.0K
Aug 7, 2026	Elefant Dov Chief Financial Officer	AWARD	15,625 sh
Aug 7, 2026	Elefant Dov Chief Financial Officer	AWARD	15,625 sh
Aug 7, 2026	Canning John Charles Chief Operating Officer	BUY	$14.0K
Aug 7, 2026	Canning John Charles Chief Operating Officer	AWARD	4,375 sh

Earnings setup

Estimates

Nov 12

reports in 17 days

−$0.60

EPS estimate, this quarter

+60%

estimate change, 90 days

2↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$1.500

90d

−$1.500

60d

−$0.600

30d

−$0.605

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.60	-$0.68–-$0.53	-0.8%	$619.5K
Next Q	-$0.51	-$0.56–-$0.46	-3.0%	$687.5K
Current FY	-$2.60	-$3.03–-$2.17	-1.2%	$2.1M
Next FY	-$2.13	-$2.59–-$1.66	+0.0%	$8.9M